BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 17054399)

  • 21. Clinical genetics of Kallmann syndrome.
    Dodé C; Hardelin JP
    Ann Endocrinol (Paris); 2010 May; 71(3):149-57. PubMed ID: 20362962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kallmann syndrome in women: from genes to diagnosis and treatment.
    Meczekalski B; Podfigurna-Stopa A; Smolarczyk R; Katulski K; Genazzani AR
    Gynecol Endocrinol; 2013 Apr; 29(4):296-300. PubMed ID: 23368665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of two novel missense mutations in the KAL1 gene in Han Chinese subjects with Kallmann Syndrome.
    Jap TS; Chiu CY; Lirng JF; Won GS
    J Endocrinol Invest; 2011 Jan; 34(1):53-9. PubMed ID: 20530987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic and genotypic landscape of PROKR2 in neuroendocrine disorders.
    Martinez-Mayer J; Perez-Millan MI
    Front Endocrinol (Lausanne); 2023; 14():1132787. PubMed ID: 36843573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hypogonadotropic hypogonadism: new aspects in the regulation of hypothalamic-pituitary-gonadal axis].
    Brioude F; Bouvattier CE; Lombès M
    Ann Endocrinol (Paris); 2010 Sep; 71 Suppl 1():S33-41. PubMed ID: 21237329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The PROK2/PROKR2 signaling pathway is required for the migration of most olfactory bulb interneurons.
    Wen Y; Zhang Z; Li Z; Liu G; Tao G; Song X; Xu Z; Shang Z; Guo T; Su Z; Chen H; You Y; Li J; Yang Z
    J Comp Neurol; 2019 Dec; 527(18):2931-2947. PubMed ID: 31132148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PROKR2 mutations in autosomal recessive Kallmann syndrome.
    Tommiska J; Toppari J; Vaaralahti K; Känsäkoski J; Laitinen EM; Noisa P; Kinnala A; Niinikoski H; Raivio T
    Fertil Steril; 2013 Mar; 99(3):815-8. PubMed ID: 23200691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Homozygous mutation in the prokineticin-receptor2 gene (Val274Asp) presenting as reversible Kallmann syndrome and persistent oligozoospermia: case report.
    Sinisi AA; Asci R; Bellastella G; Maione L; Esposito D; Elefante A; De Bellis A; Bellastella A; Iolascon A
    Hum Reprod; 2008 Oct; 23(10):2380-4. PubMed ID: 18596028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PROKR2 variants in multiple hypopituitarism with pituitary stalk interruption.
    Reynaud R; Jayakody SA; Monnier C; Saveanu A; Bouligand J; Guedj AM; Simonin G; Lecomte P; Barlier A; Rondard P; Martinez-Barbera JP; Guiochon-Mantel A; Brue T
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E1068-73. PubMed ID: 22466334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PROK2/PROKR2 Signaling and Kallmann Syndrome.
    Dodé C; Rondard P
    Front Endocrinol (Lausanne); 2013; 4():19. PubMed ID: 23596439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Congenital hypogonadotropic hypogonadism in females: clinical spectrum, evaluation and genetics.
    Bry-Gauillard H; Trabado S; Bouligand J; Sarfati J; Francou B; Salenave S; Chanson P; Brailly-Tabard S; Guiochon-Mantel A; Young J
    Ann Endocrinol (Paris); 2010 May; 71(3):158-62. PubMed ID: 20363464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biased signaling through G-protein-coupled PROKR2 receptors harboring missense mutations.
    Sbai O; Monnier C; Dodé C; Pin JP; Hardelin JP; Rondard P
    FASEB J; 2014 Aug; 28(8):3734-44. PubMed ID: 24830383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pleiotropic effects of prokineticin 2 in the control of energy metabolism.
    Magnan C; Migrenne-Li S
    Biochimie; 2021 Jul; 186():73-81. PubMed ID: 33932486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prokineticins in central and peripheral control of human reproduction.
    Traboulsi W; Brouillet S; Sergent F; Boufettal H; Samouh N; Aboussaouira T; Hoffmann P; Feige JJ; Benharouga M; Alfaidy N
    Horm Mol Biol Clin Investig; 2015 Nov; 24(2):73-81. PubMed ID: 26574895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The recent genetics of hypogonadotrophic hypogonadism - novel insights and new questions.
    Semple RK; Topaloglu AK
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):427-35. PubMed ID: 19719764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism.
    Bianco SD; Kaiser UB
    Nat Rev Endocrinol; 2009 Oct; 5(10):569-76. PubMed ID: 19707180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel fibroblast growth factor receptor 1 mutations in patients with congenital hypogonadotropic hypogonadism with and without anosmia.
    Trarbach EB; Costa EM; Versiani B; de Castro M; Baptista MT; Garmes HM; de Mendonca BB; Latronico AC
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4006-12. PubMed ID: 16882753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diversity in fibroblast growth factor receptor 1 regulation: learning from the investigation of Kallmann syndrome.
    Kim SH; Hu Y; Cadman S; Bouloux P
    J Neuroendocrinol; 2008 Feb; 20(2):141-63. PubMed ID: 18034870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel function of miR-3195 for mutant PROK2 (c.223-4C>A) degradation.
    Zhou S; Li P
    Cell Biol Int; 2021 Feb; 45(2):404-410. PubMed ID: 33140874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sexually dimorphic distribution of Prokr2 neurons revealed by the Prokr2-Cre mouse model.
    Mohsen Z; Sim H; Garcia-Galiano D; Han X; Bellefontaine N; Saunders TL; Elias CF
    Brain Struct Funct; 2017 Dec; 222(9):4111-4129. PubMed ID: 28616754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.